Nov 5 (Reuters) - Biotech firm Bio-Techne ( TECH )

missed its first-quarter revenue estimates on Wednesday, hurt by

sluggish demand for its products amid soft biotech funding

environment in China.

Shares of the Minneapolis, Minnesota-based company, which

develops products used in medical research, drug development and

diagnostics, were down nearly 10% premarket following the

results.

"During the quarter, we observed encouraging signs of

stabilization in our U.S. academic end-market and continued

strength from large pharmaceutical customers, while funding

headwinds persisted for emerging biotech companies," CEO Kim

Kelderman said.

However, peers Thermo Fisher and Danaher ( DHR )

flagged renewed demand for their services as pharmaceutical

firms ramp up drug development and manufacturing in the U.S.

while navigating President Donald Trump's shifting policies.

Bio-Techne ( TECH ) said last quarter it expects uncertainty related

to Trump's tariff and academic funding policies to spill into

fiscal 2026 and create pressure on its performance.

The company posted adjusted profit per share of 42 cents

for the quarter ended September 30, in line with analysts'

average estimate of 42 cents, according to data compiled by

LSEG.

Its quarterly revenue came in at $286.6 million, missing

estimates of $291.2 million.

Sales at its largest protein sciences unit, which develops

and manufactures biological compounds used for research and

diagnostics, fell 1% to $202.2 million during the quarter.

Quarterly revenue from its diagnostics and genomics unit,

which manufactures tools and compounds used to make therapeutics

and vaccines, fell 4% to $79.5 million.